Evolution Research Group
430 Mountain Avenue, Suite 302
New Providence, NJ 07974
www.ergclinical.com
Office: 908.756.4411 | Fax: 908.756.1122
Email: info@ergclinical.com

Hepatitis C Case Study

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Escalating, Multiple, Oral Doses of XXXX in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection

St. Louis Clinical Trials

Phase: 1 First-in-Human
Indication: Hepatitis C
Study Population: Treatment-naïve, chronically-infected HCV subjects
# of Subjects: 19 randomized and completed – highest enrolling of 13 total study sites, with 27% of total subjects
Cohorts: 6 unique dosing cohorts:

- Cohort 1: Genotype 1a
- Cohort 2: Genotype 1a
- Cohort 3: Genotype 1a
- Cohort 4: Genotype 1a
- Cohort 5: Genotype 1b
- Cohort 6: Genotype 1b

Study Duration: 5 months
In-patient Period: 5 days

Key Elements:

- 100% Retention
- Highest Enrolling Site
- Rapid Start Site

OBJECTIVES

Primary

- To evaluate the safety and tolerability of escalating, multiple, oral doses of XXXX in subjects with chronic genotype 1 Hepatitis C Virus (HCV) infection.
- To evaluate the antiviral activity of XXXX against genotype 1 HCV following administration of multiple oral doses.

Secondary

- To characterize the plasma pharmacokinetics of XXXX following administration of escalating, multiple, oral doses in genotype 1 HCV-infected subjects.
- To assess the PK/PD relationship between HCV viral load change and XXXX plasma concentrations following multiple dose administration.
- To compare XXXX antiviral activity in genotype 1a versus 1b infections.
- To evaluate genotypic changes from baseline in the NS5A coding region of HCV following multiple dose administration of XXXX and for up to 48 weeks thereafter.

Lab Assessments - 95 per subject

Hematology, Serum Chemistry, Lipids
HBV, HCV, and HIV Serology
HCV Genotype
Prothrombin time/INR
Serial Plasma HCV RNA
Serial Pharmacokinetic Analysis
Plasma for Resistance Surveillance
IL28B Genotyping
Plasma/Serum for Storage

Safety Assessments - 10 per subject
Time point specific Vitals Signs and 12-Lead ECG